Drug Profile
Multiple sclerosis vaccine - Aixlie
Latest Information Update: 22 May 2002
Price :
$50
*
At a glance
- Originator Ohio State University
- Developer Aixlie Pharmaceuticals; Ohio State University
- Class Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 22 May 2002 Discontinued - Preclinical for Multiple sclerosis in USA (unspecified route)
- 08 Feb 2001 New profile
- 08 Feb 2001 The vaccine is available for licensing (http://hometown.aol.com/aixlie/)